Investors continuously seek ways to secure long-term wealth, and one of the most effective methods remains the straightforward strategy of buying and holding shares of well-established companies. Amidst the current economic landscape, two healthcare giants, Johnson & Johnson and Merck, are standing out as viable options that could enhance a diversified portfolio and offer potential for robust returns.
Both companies have demonstrated remarkable share price growth over the past six months, outperforming the broader market indices. Although it remains uncertain if they will maintain this upward momentum throughout the year, their long-term prospects appear strong, making them worthy of consideration for investors looking to hold onto their shares for the next two decades.
Johnson & Johnson and Merck are recognized as leading players in the pharmaceutical industry, each with unique offerings that contribute to their resilience. Merck, for instance, specializes significantly in oncology. Its flagship drug, Keytruda, is currently the highest-grossing cancer treatment globally, approved for various cancer types and continually expanding its applications. This strategic flexibility places Merck in a favorable position even as it approaches a crucial point in 2028 when the patent on Keytruda is set to expire. In anticipation, the company has developed a subcutaneous version of the drug, making it easier to administer without sacrificing effectiveness. Additionally, Merck has introduced new treatments such as Winrevair for pulmonary arterial hypertension and Capvaxive, a pneumonia vaccine.
Reflecting on their structural health, Johnson & Johnson has consistently generated stable revenues and earnings, navigating challenges like patent expirations and tariffs with an impressive array of pharmaceutical products and a significant presence in the medical device market. The company has built a legacy of strong performance, supported by a diversified portfolio that positions it well for future growth.
As of recent market activity, Merck shares show a slight decline, with a current price of $108.18 and a market capitalization of $269 billion. Its performance metrics indicate a robust gross margin of 75.81% and a dividend yield of 3.03%. On the other hand, Johnson & Johnson is trading at $220.26 with a market cap of $530 billion, offering a gross margin of 75.27% and a consistent dividend yield of 2.33%.
An important factor contributing to the appeal of these stocks is their commitment to returning value to shareholders through dividends. Historically, dividend stocks tend to offer better returns than their non-dividend counterparts, as companies able to maintain dividend payments typically possess strong operational fundamentals. Merck boasts a forward yield of 3.1% and a remarkable 94% increase in its dividend payout over the last decade. Meanwhile, Johnson & Johnson is recognized as a “Dividend King,” having raised its dividend for 63 consecutive years, demonstrating its reliability and financial strength.
For long-term investors, the reinvestment of dividends is a strategy that can significantly enhance total returns over time. This aspect reinforces the case for maintaining investments in both Johnson & Johnson and Merck, with an outlook that extends well into the next two decades. As these companies continue to innovate and adapt in the ever-evolving healthcare landscape, their potential for sustained growth and stability makes them compelling choices for investors committed to building wealth over time.
